Gengos Andrew's Insider Trades & SAST Disclosures
Gengos Andrew's most recent trade in Terns Pharmaceuticals Inc was a trade of 750,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gengos Andrew.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals Inc | Andrew Gengos | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 750,000 | 750,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Andrew Gengos | CFO and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 1.34 per share. | 03 Sep 2024 | 10,000 | 93,804 | - | 1.3 | 13,400 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | CFO and Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 5,000 | 98,804 | - | 0 | Common Stock | |
| Athira Pharma Inc | Andrew Gengos | CFO and Chief Business Officer | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 03 Sep 2024 | 1,272 | 97,532 | - | 0.6 | 720 | Common Stock |
| Athira Pharma Inc | Gengos Andrew | CFO AND CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 280,000 | 280,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Gengos Andrew | See Below | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 5,000 | 85,012 | - | 0 | Common Stock | |
| Athira Pharma Inc | Andrew Gengos | CFO AND CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 5,000 | 85,012 | - | 0 | Common Stock | |
| Athira Pharma Inc | Andrew Gengos | See Below | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 1,208 | 83,804 | - | 2.9 | 3,515 | Common Stock |
| Athira Pharma Inc | Gengos Andrew | CFO AND CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 2.91 per share. | 04 Jan 2024 | 1,208 | 83,804 | - | 2.9 | 3,515 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.44 per share. | 07 Jun 2023 | 11,719 | 80,012 | - | 3.4 | 40,308 | Common Stock |
| Athira Pharma Inc | Gengos Andrew | See Below | Purchase of securities on an exchange or from another person at price $ 3.40 per share. | 07 Jun 2023 | 2,859 | 68,293 | - | 3.4 | 9,721 | Common Stock |
| Athira Pharma Inc | Gengos Andrew | See Below | Purchase of securities on an exchange or from another person at price $ 3.36 per share. | 07 Jun 2023 | 422 | 65,434 | - | 3.4 | 1,417 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 02 Jun 2023 | 15,000 | 35,012 | - | 3 | 45,000 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 2.75 per share. | 02 Jun 2023 | 10,012 | 10,012 | - | 2.8 | 27,533 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.02 per share. | 02 Jun 2023 | 10,000 | 65,012 | - | 3.0 | 30,154 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 02 Jun 2023 | 10,000 | 55,012 | - | 3.0 | 29,999 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 02 Jun 2023 | 10,000 | 45,012 | - | 3.0 | 29,997 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 2.86 per share. | 02 Jun 2023 | 6,582 | 16,594 | - | 2.9 | 18,823 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Purchase of securities on an exchange or from another person at price $ 2.94 per share. | 02 Jun 2023 | 3,418 | 20,012 | - | 2.9 | 10,066 | Common Stock |
| Athira Pharma Inc | Andrew Gengos | See Below | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 400,000 | 400,000 | - | - | Stock Options (right to buy) | |
| Cyteir Therapeutics Inc | Andrew Gengos | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges